[Long-lasting LDL-C lowering: silence at last].

Autor:	Achard M; Service de cardiologie, HUG, 1211 Genève 14., Buhayer A; Prism Scientific Sàrl, Avenue Krieg 7, 1208 Genève., Dobretz K; Service de cardiologie, HUG, 1211 Genève 14., Ehret G; Service de cardiologie, HUG, 1211 Genève 14., Mach F; Service de cardiologie, HUG, 1211 Genève 14.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2021 May 26; Vol. 17 (740), pp. 1039-1046.
Abstrakt:	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is responsible for the degradation of the LDL-receptor. Inclisiran is a new synthetic interfering ribonucleic acid (siRNA) lowers LDL-cholesterol (LDL-C) levels in the blood by using RNA silencing technology to reduce the production of PCSK9. Inclisiran administered subcutaneously at 0 and 3 months, and then every 6 months has been shown to reduce LDL-C by approximately 50 % in patients at high and very-high cardiovascular risk, or with a diagnosis of familial hypercholesterolemia, but also in patients intolerant to statins. New data are expected, in particular with cardiovascular clinical endpoints, as well as safety for use in adolescents. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu